# Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

> **NCT01745367** · PHASE2 · TERMINATED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Tivozanib Hydrochloride
- **DRUG:** paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01745367
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2020-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745367, "Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01745367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*